A real-time AI risk-prediction system inside a clinical trial is one of the better-defined opportunities in pharma. The data exists, the failure modes (protocol deviations, late-detected adverse events, site quality drift) are well understood, and the operational benefit is concrete. The structural risk is not whether the model can be built. It is whether the proof-of-concept that builds it produces artefacts that the downstream Computer System Validation team can actually reuse. That is the question this article is about. The model is the easy part. The methodology around it is what determines whether the work survives validation or has to be redone. Why a generic AI POC fails inside pharma The standard AI POC methodology optimises for an honest technical signal in six to twelve weeks: a scoped use case, success criteria agreed before work starts, and a deliberate intermediate artefact around month three so stakeholders can see progress. For most industries, that structure is right. Applied to a regulated pharma context without modification, it produces a POC that demonstrates the model works and almost nothing else. The training data is pulled from a shared drive with no captured lineage. The validation set is whatever the notebook had loaded at the time. Test evidence lives in Jupyter cells and screenshots. Risk assessment, where it exists, is informal. When the system later enters Computer System Validation, the validation team finds none of the artefacts they need and starts from zero. A twelve-week POC becomes a nine-month re-derivation. What goes wrong, specifically Three things tend to collapse the validation case at handover: Data lineage is undocumented. The POC team knows where the training set came from. They cannot reconstruct, six months later, which extracts were used, which transformations were applied, and in what order. A CSV reviewer cannot accept “we remember it was the May pull.” No version-controlled snapshots exist. The training, validation, and test splits were regenerated each notebook run. There is no frozen artefact a reviewer can reproduce. Across our pharma engagements this is the single most common reason validation handover stalls — a directionally consistent observation, not a benchmarked rate. Test evidence is ad-hoc. Performance metrics exist in slides. They are not packaged as IQ/OQ-style protocols with pre-declared acceptance criteria, executed runs, and signed reviewer evidence. Rewriting them after the fact is possible but expensive and looks reconstructed — because it is. The decision sitting underneath all of this is whether the system falls under GxP regulatory scope at all. If it does, the validation expectations are not optional. The right place to make that determination is at POC kickoff, not at validation handover. What changes when the POC is instrumented for validation from week one A pharma-aware POC keeps the same six-to-twelve-week shape and the same intermediate-artefact discipline. It adds five concrete instrumentation requirements. Each adds modest overhead — five to fifteen per cent of POC effort in our experience, not a benchmarked figure — and together they remove the re-derivation cost at the validation gate. The five instrumentation requirements Requirement What it produces What it prevents 1. Data lineage captured per training run Sources, transformations, timestamps logged automatically with each model build Reviewer cannot reconstruct the training corpus 2. Version-controlled dataset snapshots Frozen training, validation, and test splits with cryptographic hashes Reviewer cannot reproduce reported metrics 3. IQ/OQ-style test evidence packaging Pre-declared acceptance criteria, executed runs, reviewer-signed protocols Performance evidence rejected as reconstructed 4. Risk assessment mapped to GxP impact taxonomy Model failure modes classified by patient-safety and data-integrity impact Validation team starts the risk register from zero 5. Change-control plan for post-deployment updates Defined process for retraining, revalidation triggers, and audit trail First model update breaks the validation envelope None of these requirements are theoretical. They are the artefacts a Computer System Validation reviewer expects to find. The choice is whether they are produced as the POC runs, or reconstructed afterwards under time pressure. How this reframes the clinical-trial risk model For a real-time risk-prediction system specifically — site quality flags, adverse-event detection, protocol-deviation prediction — instrumentation matters more than for almost any other AI use case in pharma. The model influences clinical operations decisions. The intended-use statement therefore carries weight. The data lineage covers patient-derived data, which means privacy controls (GDPR, HIPAA depending on jurisdiction) belong inside the validation package, not bolted on later. The performance envelope — sensitivity and specificity at the operating threshold, behaviour under data drift — must be characterised against frozen test data the reviewer can re-run. The model itself is comparatively conventional. The discipline that surrounds it is what determines whether it ships. How does the POC team work with QA early enough? The most common failure pattern is QA arriving at validation handover with no prior context. The POC team has done six months of work; the QA team has seen none of it. The fix is structural rather than procedural: a single QA reviewer attends the POC kickoff, signs off on the intended-use statement, reviews the five instrumentation requirements before week one of model work, and reviews the intermediate artefact around month three. This is a few hours of QA time spread across the POC. It is not a parallel validation programme. We have found this early-engagement pattern reliably reduces validation surprise. It does not eliminate findings — reviewers will still find things — but the findings tend to be specific and addressable rather than structural and project-killing. FAQ How do I run an AI POC in pharma so the output survives downstream GxP validation? Instrument it for validation from week one. Add five things to the standard POC: data lineage capture per training run, version-controlled dataset snapshots, IQ/OQ-style test evidence packaging, risk assessment mapped to the GxP impact taxonomy, and a change-control plan for post-deployment model updates. Done at POC time, this adds modest overhead. Done later, it forces re-derivation. Which POC decisions create rework when the system enters validation? Pulling training data without lineage capture, regenerating dataset splits each notebook run instead of freezing them, recording performance in slides instead of pre-declared test protocols, and deferring the risk assessment until validation. Each of these decisions is invisible during the POC and expensive afterwards. What validation-ready artifacts must come out of a pharma AI POC? At minimum: an intended-use statement signed by QA, documented data lineage per training run, version-controlled training/validation/test snapshots with hashes, IQ/OQ-style executed test evidence, a model performance envelope with declared operating thresholds, a risk assessment against the GxP impact taxonomy, and a change-control plan. How is a pharma POC scoped differently from a generic AI POC? The shape is the same — six to twelve weeks, agreed success criteria, an intermediate artefact at month three. The difference is that every POC deliverable doubles as a validation deliverable. The data extracts are logged because the validation reviewer will ask. The test runs are formalised because the validation reviewer will re-run them. The risk register exists because the validation reviewer will expect it. Where do pharma AI POCs that ignore GxP scope tend to collapse? At validation handover. The model demonstrably works, the team is confident, and then the validation team asks for evidence that does not exist. The collapse is rarely about the model’s quality; it is about the absence of reconstructible evidence. The downstream timeline impact is observed to be in the range of six to nine months of re-derivation — a directional pattern across pharma engagements, not a published benchmark. How does the POC team work with QA early so the validation package starts at POC rather than after it? One QA reviewer attached to the POC from kickoff, present at the intended-use sign-off, briefed on the five instrumentation requirements before model work begins, and reviewing the intermediate artefact at month three. A few hours of QA time across the POC, not a parallel programme. Where this fits This article is the pharma-specific specialisation of the general AI POC methodology. The general methodology is correct; pharma adds five non-optional instrumentation requirements that change what the POC produces without changing its shape. We work with pharma and biotech teams on exactly this overlap — building AI systems that handle the clinical-trial risk-prediction task and producing the validation artefacts the GxP environment expects. The model is the visible deliverable. The artefacts are what determine whether it ships. References FDA (2023) Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations. [online] Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations NIST (2023) AI Risk Management Framework. [online] Available at: https://www.nist.gov/itl/ai-risk-management-framework Nature (2025) Generative AI: A Generation-Defining Shift for Biopharma. [online] Available at: https://www.nature.com/articles/d41573-025-00089-9.pdf Image credits: DC Studio at Freepik.
